[144] Alignment Healthcare, Inc. SEC Filing

Rhea-AI Filing Summary

Alignment Healthcare, Inc. (ALHC) filing a Form 144 notifies the proposed sale of 120,000 shares of common stock through E-Trade, with an aggregate market value of $1,903,200. The filer acquired the securities as restricted stock units that vested on 09/12/2022 (215,662 units granted under the 2021 Equity Incentive Plan). The filing reports recent Rule 10b5-1 plan sales by the same seller: three sales of 30,000 shares each on 06/16/2025, 07/14/2025, and 08/13/2025, generating gross proceeds of $434,280, $403,347, and $447,108 respectively. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.

Positive

• Compliance with disclosure rules: Form 144 filed and recent 10b5-1 sales disclosed, showing adherence to insider trading procedures
• Planned liquidity from compensation: Shares originate from RSU vesting under the 2021 Equity Incentive Plan, a routine compensation mechanism

Negative

• Insider selling: Proposed sale of 120,000 shares and prior sales of 90,000 shares in three months may be perceived negatively by some investors despite routine nature

Insights

Securities Analyst

TL;DR: Insider plans to sell vested RSUs under a brokered transaction; recent systematic 10b5-1 sales suggest planned liquidity rather than ad hoc disposition.

The proposed sale of 120,000 shares equals about 0.06% of the reported outstanding shares (198,031,417), and the securities were acquired via RSU vesting on 09/12/2022. Prior 10b5-1 transactions in June–August 2025 show orderly disposals of 90,000 shares totaling roughly $1.28 million. From a market-impact perspective, the size of the proposed sale is immaterial to company capitalization. For investors, the filing documents routine insider liquidity from equity compensation rather than an indicated change in company fundamentals.

Corporate Governance Expert

TL;DR: The filing is a routine disclosure required under Rule 144; use of 10b5-1 plans aligns with compliance best practices for insider trades.

The transaction stems from vested RSUs under the 2021 Equity Incentive Plan and is being executed via an established broker. The seller attests to no undisclosed material adverse information and references adoption of Rule 10b5-1 trading instructions for prior sales. Governance-wise, this is a standard, compliant insider liquidity event; the filing contains no indications of unusual timing or exception that would raise control or disclosure concerns.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	E-Trade Finance PO Box 101600 Arlington VA 22210-4600	120000	1903200	198031417	09/08/2025	Nasdaq Stock Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/12/2022	The Common Stock was acquired through the vesting of restricted stock units granted on 09/12/2022 under the Issuer's 2021 Equity Incentive Plan	Alignment Healthcare, Inc. (Issuer)			215662	09/12/2022	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales Plan for Dawn Maroney 1100 W. Town & Country Road, Suite 1600 Orange CA 92868	Common Stock	08/13/2025	30000	447108
10b5-1 Sales Plan for Dawn Maroney 1100 W. Town & Country Road, Suite 1600 Orange CA 92868	Common Stock	07/14/2025	30000	403347
10b5-1 Sales Plan for Dawn Maroney 1100 W. Town & Country Road, Suite 1600 Orange CA 92868	Common Stock	06/16/2025	30000	434280

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What is the size and value of the proposed sale in the ALHC Form 144?

The filing proposes sale of 120,000 common shares with an aggregate market value of $1,903,200 via E-Trade.

How were the shares being sold by the ALHC filer acquired?

The shares were acquired as restricted stock units that vested on 09/12/2022 under Alignment Healthcare's 2021 Equity Incentive Plan, totaling 215,662 units acquired on that date.

Has the filer recently sold ALHC shares?

Yes. The Form 144 reports three 10b5-1 plan sales of 30,000 shares each on 06/16/2025, 07/14/2025, and 08/13/2025, with gross proceeds of $434,280, $403,347, and $447,108 respectively.

Does the filing indicate undisclosed negative information about ALHC?

No. The signer represents they do not know any material adverse information that has not been publicly disclosed.

What broker will execute the proposed sale?

The filing lists E-Trade (address noted) as the broker for the proposed transaction.